New investigational antifungal agents for treating invasive fungal infections
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Systemic fungal infections have been recognised as a major cause of morbidity and mortality during the last two decades. There are only a few therapeutic options for these infections. Severe toxicity, such as impairment of renal function, limits the use of amphotericin B. Flucytosine is associated with side effects and drug resistance. Fluconazole and itraconazole are safer, though emergence of resistance and innate resistance in some fungal pathogens is a concern in their use. Therefore, there is a need for developing novel drugs and/or treatment strategies to combat these infections. In recent years, increased efforts by the pharmaceutical industry and academia have led to the discovery of new re-engineered or reconsidered antifungal agents that are more efficacious, safer and have a broad spectrum of activity. Lipid formulations of polyene antifungal agents, amphotericin B and nystatin, have the advantage of improved therapeutic index. Activity against resistant fungi, high bioavailability, safety and longer half-life are the properties that encourage development of the newer triazoles (e.g., voriconazole, ravuconazole and posaconazole). Echinocandin-like lipopeptide antibiotics are among the antifungal agents with a novel mode of action. In addition to these lead investigational compounds, development of newer antifungal agents is underway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Prasad, R., De Wergifosse, P., Goffeau, A., & Balzi, E. (1995) · Current Genetics · doi:10.1007/bf00352101 · Cited by 486
Mode of action of 5-fluorocytosine and mechanisms of resistance
Polak, A., & Scholer, H. J. (2009) · Chemotherapy · doi:10.1159/000221854 · Cited by 250 · cited 1×
“resulting in the disruption of protein synthesis [26].”
BackgroundHector, R. F., Zimmer, B. L., & Pappagianis, D. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.4.587 · Cited by 189
In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata
DEFONTAINE, A., BOUCHARA, J.-P., DECLERK, P., PLANCHENAULT, C., CHABASSE, D., & HALLET, J.-N. (1999) · Journal of Medical Microbiology · doi:10.1099/00222615-48-7-663 · Cited by 65 · cited 5×
“5-FU is also converted to 5-fluorodeoxyuridine monophosphate, a potent inhibitor of thymidine synthase, an enzyme involved in DNA synthesis and nuclear division [27].”
BackgroundInfluential
Cited by
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Campoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511
WALSH, T. J., LUTSAR, I., DRISCOLL, T., DUPONT, B., RODEN, M., GHAHRAMANI, P., HODGES, M., GROLL, A. H., & PERFECT, J. R. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200203000-00015 · Cited by 431
Walsh, T. J., Karlsson, M. O., Driscoll, T., Arguedas, A. G., Adamson, P., Saez-Llorens, X., Vora, A. J., Arrieta, A. C., Blumer, J., Lutsar, I., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2166-2172.2004 · Cited by 335
Shafiei, M., Peyton, L., Hashemzadeh, M., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104240 · Cited by 295
“Their newer generation further increased highly desired properties such as safety, lower risk of drug-drug interactions, proper pharmacokinetics, and improved activity spectrum [25–27].”
Metadata
- Authors
- Hossain, M. A., & Ghannoum, M. A.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2000-08
- Volume
- 9
- Issue
- 8
- Pages
- 1797-1813
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W1971237695
- Cited by
- 95
- References
- 5
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New investigational antifungal agents for treating invasive fungal infections. https://app.cochat.ai/papers/10.1517/13543784.9.8.1797
- The paper
- Hossain, M. A., & Ghannoum, M. A. (2000). New investigational antifungal agents for treating invasive fungal infections. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.9.8.1797
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.